Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...
Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (Keytruda) in the KeyVibe programme. Favezelimab is being evaluated as an investigational fixed-dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback